person · Reporting owner

BLICKENSTAFF KIM D

Disclosed activity across 4 companies

Tapewire entity: 44250
SEC CIK: 0001238913

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Nuvation Bio Inc.NUVB · Entity 4384	Director	May 21, 2026	May 27, 2026
Opy Acquisition Corp. IOHAA · Entity 133726	Director	October 26, 2021	October 27, 2021
TANDEM DIABETES CARE INCTNDM · Entity 4682	Director	November 20, 2024	November 22, 2024

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Nuvation Bio Inc.

Report date May 21, 2026 · Filed May 27, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.79 · Expires 2036-05-20	Direct	123,397	Reported balance After 2026-05-21 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-05-21 · Grant · Acquired 123,397 · Balance 123,397 F1: 100% of the shares subject to the option shall vest on the earlier of: (i) the one-year anniversary of the grant date (May 21, 2026); or (ii) the next shareholder annual meeting, subject to the Reporting Person's continuous service through such applicable vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: 100% of the shares subject to the option shall vest on the earlier of: (i) the one-year anniversary of the grant date (May 21, 2026); or (ii) the next shareholder annual meeting, subject to the Reporting Person's continuous service through such applicable vesting date.

Opy Acquisition Corp. I

Report date October 26, 2021 · Filed October 27, 2021

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	0	Reported balance Holding disclosure · report date 2021-10-26 · row 1 Holding and transaction disclosures are not merged. 1 source row Row 1 · Balance 0

TANDEM DIABETES CARE INC

Report date November 20, 2024 · Filed November 22, 2024

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectSee Footnote	165,190	Last balance in matching sequence After 2024-11-21 transaction · row 2 Source-order balances reconcile. Account continuity and personal attribution are not independently verified. 2 source rows Row 1 · 2024-11-20 · Sale · Disposed 10,000 · Balance 195,190 F1: The price reported reflects the weighted average price per share of multiple transactions with prices per share ranging between $30.00 to $30.01 F2: The securities are held by the Kim Blickenstaff Revocable Trust dated April 15, 2010. Row 2 · 2024-11-21 · Sale · Disposed 30,000 · Balance 165,190 F3: The price reported reflects the weighted average price per share of multiple transactions with prices per share ranging between $31.22 to $31.63. F2: The securities are held by the Kim Blickenstaff Revocable Trust dated April 15, 2010.

Filing footnotes · ownership attribution and instrument terms

F1: The price reported reflects the weighted average price per share of multiple transactions with prices per share ranging between $30.00 to $30.01

F2: The securities are held by the Kim Blickenstaff Revocable Trust dated April 15, 2010.

F3: The price reported reflects the weighted average price per share of multiple transactions with prices per share ranging between $31.22 to $31.63.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

MEDIVATION, INC.

Report date September 28, 2016 · Filed September 30, 2016

Section 16 reporting ended · disclosed 2016-09-30. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2016-09-28 transaction · row 1 1 source row Row 1 · 2016-09-28 · Other · Disposed 43,242 · Balance 0 F1: Disposed of pursuant to an Agreement and Plan of Merger (the "Merger Agreement"), dated August 20, 2016, among the Issuer, Pfizer Inc., a Delaware corporation ("Parent"), and Montreal, Inc., a Delaware corporation and a wholly-owned subsidiary of Parent ("Purchaser"), in exchange for a cash consideration of $81.50 per share (without interest) subject to any required withholding of taxes. Pursuant to the Merger Agreement, the Purchaser merged with and into the Issuer, with the Issuer surviving as a wholly-owned subsidiary of Parent (the "Merger"). In connection with the Merger, Purchaser offered to purchase all of the outstanding shares of common stock, par value $0.01 per share of the Issuer, at a price of $81.50 per share, net to the seller in cash (without interest) but subject to any required withholding of taxes, upon the terms and conditions set forth in the offer to purchase dated August 30, 2016, and in the related letter of transmittal. F2: Includes 2,972 unvested shares subject to a restricted stock award.
Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.21 · Expires 2020-06-30	Direct	Reported balance After 2016-09-28 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2016-09-28 · Disposition to issuer · Disposed 34,500 · Balance 0 F3: This option was cancelled in the Merger in exchange for a cash payment equal to $81.50 per share (without interest) subject to any required withholding of taxes minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger.
Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.50 · Expires 2021-07-15	Direct	Reported balance After 2016-09-28 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2016-09-28 · Disposition to issuer · Disposed 60,000 · Balance 0 F3: This option was cancelled in the Merger in exchange for a cash payment equal to $81.50 per share (without interest) subject to any required withholding of taxes minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger.
Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $23.74 · Expires 2022-07-16	Direct	Reported balance After 2016-09-28 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2016-09-28 · Disposition to issuer · Disposed 30,000 · Balance 0 F3: This option was cancelled in the Merger in exchange for a cash payment equal to $81.50 per share (without interest) subject to any required withholding of taxes minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger.
Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $24.60 · Expires 2023-06-28	Direct	Reported balance After 2016-09-28 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2016-09-28 · Disposition to issuer · Disposed 12,232 · Balance 0 F3: This option was cancelled in the Merger in exchange for a cash payment equal to $81.50 per share (without interest) subject to any required withholding of taxes minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger.
Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $38.89 · Expires 2024-06-27	Direct	Reported balance After 2016-09-28 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2016-09-28 · Disposition to issuer · Disposed 9,584 · Balance 0 F3: This option was cancelled in the Merger in exchange for a cash payment equal to $81.50 per share (without interest) subject to any required withholding of taxes minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger.
Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $55.45 · Expires 2025-06-16	Direct	Reported balance After 2016-09-28 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2016-09-28 · Disposition to issuer · Disposed 6,284 · Balance 0 F3: This option was cancelled in the Merger in exchange for a cash payment equal to $81.50 per share (without interest) subject to any required withholding of taxes minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger.
Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $58.89 · Expires 2026-06-22	Direct	Reported balance After 2016-09-28 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2016-09-28 · Disposition to issuer · Disposed 6,228 · Balance 0 F3: This option was cancelled in the Merger in exchange for a cash payment equal to $81.50 per share (without interest) subject to any required withholding of taxes minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger.

Filing footnotes · ownership attribution and instrument terms

F1: Disposed of pursuant to an Agreement and Plan of Merger (the "Merger Agreement"), dated August 20, 2016, among the Issuer, Pfizer Inc., a Delaware corporation ("Parent"), and Montreal, Inc., a Delaware corporation and a wholly-owned subsidiary of Parent ("Purchaser"), in exchange for a cash consideration of $81.50 per share (without interest) subject to any required withholding of taxes. Pursuant to the Merger Agreement, the Purchaser merged with and into the Issuer, with the Issuer surviving as a wholly-owned subsidiary of Parent (the "Merger"). In connection with the Merger, Purchaser offered to purchase all of the outstanding shares of common stock, par value $0.01 per share of the Issuer, at a price of $81.50 per share, net to the seller in cash (without interest) but subject to any required withholding of taxes, upon the terms and conditions set forth in the offer to purchase dated August 30, 2016, and in the related letter of transmittal.

F2: Includes 2,972 unvested shares subject to a restricted stock award.

F3: This option was cancelled in the Merger in exchange for a cash payment equal to $81.50 per share (without interest) subject to any required withholding of taxes minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
May 21, 2026 Filed May 27, 2026 00:04 UTC	Nuvation Bio Inc. NUVB · Entity 4384	GrantStock Option (Right to Buy) · Derivative	123,397	$0.00 Strike: $4.79	$0.00	Disclosure SEC source: 0001238913-26-000002 · form4-05272026_120529.xml · derivative · entry 1 BLICKENSTAFF KIM D · CIK 0001238913 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 123,397 Underlying: Class A Common Stock · 123,397 shares Expires 2036-05-20 F1 · derivative.exercise_date: 100% of the shares subject to the option shall vest on the earlier of: (i) the one-year anniversary of the grant date (May 21, 2026); or (ii) the next shareholder annual meeting, subject to the Reporting Person's continuous service through such applicable vesting date. Read SEC document
May 21, 2025 Filed May 23, 2025 20:05 UTC	Nuvation Bio Inc. NUVB · Entity 4384	GrantStock Option (Right to Buy) · Derivative	292,983	$0.00 Strike: $2.03	$0.00	Disclosure SEC source: 0001415889-25-014417 · form4-05232025_040503.xml · derivative · entry 1 BLICKENSTAFF KIM D · CIK 0001238913 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 292,983 Underlying: Class A Common Stock · 292,983 shares Expires 2035-05-20 F1 · derivative.exercise_date: 100% of the shares subject to the option shall vest on the earlier of: (i) the one-year anniversary of the grant date (May 21, 2025); or (ii) the next shareholder annual meeting, subject to the Reporting Person's continuous service through such applicable vesting date. Read SEC document
November 21, 2024 Filed Nov 22, 2024 21:08 UTC	TANDEM DIABETES CARE INC TNDM · Entity 4682	SaleCommon Stock	30,000	$31.38	$941,400.00	Disclosure SEC source: 0001438133-24-000217 · wk-form4_1732309683.xml · nonDerivative · entry 2 BLICKENSTAFF KIM D · CIK 0001238913 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 165,190 F3 · price: The price reported reflects the weighted average price per share of multiple transactions with prices per share ranging between $31.22 to $31.63. F2 · ownership.nature: The securities are held by the Kim Blickenstaff Revocable Trust dated April 15, 2010. Read SEC document
November 20, 2024 Filed Nov 22, 2024 21:08 UTC	TANDEM DIABETES CARE INC TNDM · Entity 4682	SaleCommon Stock	10,000	$30.00	$300,000.00	Disclosure SEC source: 0001438133-24-000217 · wk-form4_1732309683.xml · nonDerivative · entry 1 BLICKENSTAFF KIM D · CIK 0001238913 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 195,190 F1 · price: The price reported reflects the weighted average price per share of multiple transactions with prices per share ranging between $30.00 to $30.01 F2 · ownership.nature: The securities are held by the Kim Blickenstaff Revocable Trust dated April 15, 2010. Read SEC document
September 03, 2024 Filed Sep 5, 2024 21:56 UTC	Nuvation Bio Inc. NUVB · Entity 4384	GrantStock Option (Right to Buy) · Derivative	200,801	$0.00 Strike: $2.98	$0.00	Disclosure SEC source: 0001415889-24-022966 · form4-09052024_090919.xml · derivative · entry 1 BLICKENSTAFF KIM D · CIK 0001238913 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 200,801 Underlying: Class A Common Stock · 200,801 shares Expires 2034-09-02 F1 · derivative.exercise_date: 100% of the shares subject to the option shall vest on the earlier of: (i) the one-year anniversary of the grant date (September 3, 2024); or (ii) the next shareholder annual meeting, subject to the Reporting Person's continuous service through such applicable vesting date. Read SEC document
June 11, 2024 Filed Jun 13, 2024 20:33 UTC	Nuvation Bio Inc. NUVB · Entity 4384	PurchaseClass A Common Stock	172,189	$2.90	$500,088.51	Disclosure SEC source: 0001415889-24-016680 · form4-06132024_080625.xml · nonDerivative · entry 1 BLICKENSTAFF KIM D · CIK 0001238913 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Trust Disclosed balance after: 172,189 F1 · price: Price reported is a weighted-average purchase price. The shares were purchased at prices ranging from $2.835 to $2.96. The reporting person will provide upon request to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares purchased at each separate price. F2 · ownership.nature: Shares are held directly by Kim D. Blickenstaff, Trustee of the Kim Blickenstaff Revocable Trust dated April 15, 2010. Read SEC document
May 24, 2024 Filed May 24, 2024 23:21 UTC	TANDEM DIABETES CARE INC TNDM · Entity 4682	Exercise / conversionRestricted Stock Unit · Derivative	4,434	$0.00	$0.00	Disclosure SEC source: 0001438133-24-000119 · wk-form4_1716592863.xml · derivative · entry 3 BLICKENSTAFF KIM D · CIK 0001238913 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,434 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Awarded on May 24, 2023 pursuant to the Tandem Diabetes Care, Inc. 2023 Long-Term Incentive Plan (the 2023 Plan). F3 · derivative.exercise_price: Each restricted stock unit (RSU) represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2023 Plan. F4 · derivative.exercise_date: RSU will vest on the one-year anniversary of the grant date, subject to the terms of the 2023 Plan. F4 · derivative.expiration_date: RSU will vest on the one-year anniversary of the grant date, subject to the terms of the 2023 Plan. Read SEC document
May 24, 2024 Filed May 24, 2024 23:21 UTC	TANDEM DIABETES CARE INC TNDM · Entity 4682	Exercise / conversionCommon Stock	4,434	$51.73	$229,370.82	Disclosure SEC source: 0001438133-24-000119 · wk-form4_1716592863.xml · nonDerivative · entry 1 BLICKENSTAFF KIM D · CIK 0001238913 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,848 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
May 23, 2024 Filed May 24, 2024 23:21 UTC	TANDEM DIABETES CARE INC TNDM · Entity 4682	GrantRestricted Stock Unit · Derivative	4,387	$0.00	$0.00	Disclosure SEC source: 0001438133-24-000119 · wk-form4_1716592863.xml · derivative · entry 4 BLICKENSTAFF KIM D · CIK 0001238913 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,387 Underlying: Common Stock · 4,387 shares Expires not disclosed F5 · security: Awarded on May 23, 2024 pursuant to the Tandem Diabetes Care, Inc. 2023 Long-Term Incentive Plan (the 2023 Plan). F3 · derivative.exercise_price: Each restricted stock unit (RSU) represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2023 Plan. F4 · derivative.exercise_date: RSU will vest on the one-year anniversary of the grant date, subject to the terms of the 2023 Plan. F4 · derivative.expiration_date: RSU will vest on the one-year anniversary of the grant date, subject to the terms of the 2023 Plan. Read SEC document
May 25, 2023 Filed May 26, 2023 20:20 UTC	TANDEM DIABETES CARE INC TNDM · Entity 4682	Exercise / conversionRestricted Stock Unit · Derivative	2,757	$0.00	$0.00	Disclosure SEC source: 0001438133-23-000111 · wf-form4_168513241953641.xml · derivative · entry 4 BLICKENSTAFF KIM D · CIK 0001238913 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,757 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · security: Awarded on May 25, 2022 pursuant to the Tandem Diabetes Care, Inc. 2013 Stock Incentive Plan, as amended, and the agreements related thereto (the 2013 Plan). F6 · derivative.exercise_price: RSU represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2013 Plan. F7 · derivative.exercise_date: RSU will vest on the one-year anniversary of the grant date, subject to the terms of the 2013 Plan. F7 · derivative.expiration_date: RSU will vest on the one-year anniversary of the grant date, subject to the terms of the 2013 Plan. Read SEC document
May 25, 2023 Filed May 26, 2023 20:20 UTC	TANDEM DIABETES CARE INC TNDM · Entity 4682	Exercise / conversionCommon Stock	2,757	$0.00	$0.00	Disclosure SEC source: 0001438133-23-000111 · wf-form4_168513241953641.xml · nonDerivative · entry 1 BLICKENSTAFF KIM D · CIK 0001238913 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,414 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
May 24, 2023 Filed May 26, 2023 20:20 UTC	TANDEM DIABETES CARE INC TNDM · Entity 4682	GrantRSU 2023 05 24 · Derivative	4,434	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001438133-23-000111 · wf-form4_168513241953641.xml · derivative · entry 3 BLICKENSTAFF KIM D · CIK 0001238913 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,434 Underlying: Common Stock · 4,434 shares Expires not disclosed F2 · security: Awarded on May 24, 2023 pursuant to the Tandem Diabetes Care, Inc. 2023 Long-Term Incentive Plan (the 2023 Plan). F3 · derivative.exercise_price: Each restricted stock unit (RSU) represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2023 Plan. F4 · derivative.exercise_date: RSU will vest on the one-year anniversary of the grant date, subject to the terms of the 2023 Plan. F4 · derivative.expiration_date: RSU will vest on the one-year anniversary of the grant date, subject to the terms of the 2023 Plan. Read SEC document
May 15, 2023 Filed May 17, 2023 21:12 UTC	Nuvation Bio Inc. NUVB · Entity 4384	GrantStock Option (Right to Buy) · Derivative	366,744	$0.00 Strike: $1.64	$0.00	Disclosure SEC source: 0001209191-23-030281 · doc4.xml · derivative · entry 1 BLICKENSTAFF KIM D · CIK 0001238913 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 366,744 Underlying: Class A Common Stock · 366,744 shares Expires 2033-05-14 F1 · derivative.exercise_date: 100% of the shares subject to the option shall vest on the earlier of: (i) the one-year anniversary of the grant date (May 15, 2024); or (ii) the next shareholder annual meeting, subject to the Reporting Person's continuous service through such applicable vesting date. Read SEC document
May 25, 2022 Filed May 28, 2022 01:43 UTC	TANDEM DIABETES CARE INC TNDM · Entity 4682	GrantRestricted Stock Unit · Derivative	2,757	$0.00	$0.00	Disclosure SEC source: 0001438133-22-000118 · wf-form4_165370220405871.xml · derivative · entry 3 BLICKENSTAFF KIM D · CIK 0001238913 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,757 Underlying: Common Stock · 2,757 shares Expires not disclosed F2 · security: Awarded on May 25, 2022 pursuant to the Tandem Diabetes Care, Inc. 2013 Stock Incentive Plan, as amended, and the agreements related thereto (the "2013 Plan"). F3 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2013 Plan. F4 · derivative.exercise_date: RSU will vest on the one-year anniversary of the grant date, subject to the terms of the 2013 Plan. F4 · derivative.expiration_date: RSU will vest on the one-year anniversary of the grant date, subject to the terms of the 2013 Plan. Read SEC document
May 18, 2022 Filed May 19, 2022 23:14 UTC	TANDEM DIABETES CARE INC TNDM · Entity 4682	Exercise / conversionRestricted Stock Unit · Derivative	2,205	$0.00	$0.00	Disclosure SEC source: 0001438133-22-000087 · wf-form4_165300203905899.xml · derivative · entry 7 BLICKENSTAFF KIM D · CIK 0001238913 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,205 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · security: Awarded on May 18, 2021 pursuant to the 2013 Plan, as amended, and the agreements related thereto. F8 · derivative.exercise_price: Each restricted stock (RSU) unit represents a contingent right to receive one share of common stock of the Company. F9 · derivative.exercise_date: Shares will vest on the one year anniversary of the grant date, subject to the terms of the 2013 Plan. F9 · derivative.expiration_date: Shares will vest on the one year anniversary of the grant date, subject to the terms of the 2013 Plan. Read SEC document
May 18, 2022 Filed May 19, 2022 23:14 UTC	TANDEM DIABETES CARE INC TNDM · Entity 4682	Exercise / conversionCommon Stock	2,205	$0.00	$0.00	Disclosure SEC source: 0001438133-22-000087 · wf-form4_165300203905899.xml · nonDerivative · entry 2 BLICKENSTAFF KIM D · CIK 0001238913 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,657 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
May 17, 2022 Filed May 19, 2022 23:14 UTC	TANDEM DIABETES CARE INC TNDM · Entity 4682	Exercise / conversionWarrant · Derivative	13,562	$73.73 Strike: $73.73	$999,872.01	Disclosure SEC source: 0001438133-22-000087 · wf-form4_165300203905899.xml · derivative · entry 6 BLICKENSTAFF KIM D · CIK 0001238913 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 13,562 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.expiration_date: The expiration dates for these warrants are May 25, 2022 (2,712 shares), and July 3, 2022 (10,850 shares). F3 · ownership.nature: The securities are held by the Kim Blickenstaff Revocable Trust dated April 15, 2010. Read SEC document
May 17, 2022 Filed May 19, 2022 23:14 UTC	TANDEM DIABETES CARE INC TNDM · Entity 4682	Exercise / conversionStock Option · Derivative	6,560	$9.00 Strike: $9.00	$59,040.00	Disclosure SEC source: 0001438133-22-000087 · wf-form4_165300203905899.xml · derivative · entry 5 BLICKENSTAFF KIM D · CIK 0001238913 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,560 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The options vested as to twenty-five percent (25%) of the underlying shares on 5/17/2018, and the remaining shares vested in thirty-six (36) equal monthly installments thereafter, subject to the terms of Tandem Diabetes Care, Inc. 2013 Stock Incentive Plan (the 2013 Plan). F5 · derivative.expiration_date: The expiration date for these options is 10 years from the date of grant. Read SEC document
May 17, 2022 Filed May 19, 2022 23:14 UTC	TANDEM DIABETES CARE INC TNDM · Entity 4682	SaleCommon Stock	10,762	$92.91	$999,897.42	Disclosure SEC source: 0001438133-22-000087 · wf-form4_165300203905899.xml · nonDerivative · entry 4 BLICKENSTAFF KIM D · CIK 0001238913 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 205,190 F2 · kind: The transaction reflects the cashless exercise of warrants to purchase common stock, at an exercise price of $73.726. Pursuant to the terms of the warrant, the shares of common stock were sold at a price equal to the average of the closing prices of the shares over the 30-day period ending three days prior to the date on which the notice of exercise was received by the Issuer. F3 · ownership.nature: The securities are held by the Kim Blickenstaff Revocable Trust dated April 15, 2010. Read SEC document
May 17, 2022 Filed May 19, 2022 23:14 UTC	TANDEM DIABETES CARE INC TNDM · Entity 4682	Exercise / conversionCommon Stock	13,562	$73.73	$999,872.01	Disclosure SEC source: 0001438133-22-000087 · wf-form4_165300203905899.xml · nonDerivative · entry 3 BLICKENSTAFF KIM D · CIK 0001238913 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 215,952 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: The transaction reflects the cashless exercise of warrants to purchase common stock, at an exercise price of $73.726. Pursuant to the terms of the warrant, the shares of common stock were sold at a price equal to the average of the closing prices of the shares over the 30-day period ending three days prior to the date on which the notice of exercise was received by the Issuer. F3 · ownership.nature: The securities are held by the Kim Blickenstaff Revocable Trust dated April 15, 2010. Read SEC document
May 17, 2022 Filed May 19, 2022 23:14 UTC	TANDEM DIABETES CARE INC TNDM · Entity 4682	Exercise / conversionCommon Stock	6,560	$9.00	$59,040.00	Disclosure SEC source: 0001438133-22-000087 · wf-form4_165300203905899.xml · nonDerivative · entry 1 BLICKENSTAFF KIM D · CIK 0001238913 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,452 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents shares of common stock received upon exercise of a stock option award. Read SEC document
May 16, 2022 Filed May 18, 2022 20:56 UTC	Nuvation Bio Inc. NUVB · Entity 4384	GrantStock Option (Right to Buy) · Derivative	118,784	$0.00 Strike: $4.05	$0.00	Disclosure SEC source: 0001209191-22-030089 · doc4.xml · derivative · entry 1 BLICKENSTAFF KIM D · CIK 0001238913 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,784 Underlying: Class A Common Stock · 118,784 shares Expires 2032-05-15 F1 · derivative.exercise_date: 100% of the shares subject to the option shall vest on the earlier of: (i) the one-year anniversary of the grant date (May 16, 2023); or (ii) the next shareholder annual meeting, subject to the Reporting Person's continuous service through such applicable vesting date. Read SEC document
May 16, 2022 Filed Jun 28, 2022 23:08 UTC Amendment	Nuvation Bio Inc. NUVB · Entity 4384	GrantStock Option (Right to Buy) · Derivative	140,713	$0.00 Strike: $4.05	$0.00	Disclosure SEC source: 0001209191-22-039677 · doc4a.xml · derivative · entry 1 BLICKENSTAFF KIM D · CIK 0001238913 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,713 Underlying: Class A Common Stock · 140,713 shares Expires 2032-05-15 F1 · derivative.exercise_date: 100% of the shares subject to the option shall vest on the earlier of: (i) the one-year anniversary of the grant date (May 16, 2023); or (ii) the next shareholder annual meeting, subject to the Reporting Person's continuous service through such applicable vesting date. Read SEC document
October 29, 2021 Filed Nov 3, 2021 01:33 UTC	Nuvation Bio Inc. NUVB · Entity 4384	GrantStock Option (Right to Buy) · Derivative	45,229	$0.00 Strike: $9.17	$0.00	Disclosure SEC source: 0001209191-21-062589 · doc4.xml · derivative · entry 1 BLICKENSTAFF KIM D · CIK 0001238913 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,229 Underlying: Class A Common Stock · 45,229 shares Expires 2031-10-28 F1 · derivative.exercise_date: 100% of the shares subject to the option shall vest on the earlier of: (i) the one-year anniversary of the grant date (October 29, 2022); or (ii) the next shareholder annual meeting, subject to the Reporting Person's continuous service through such applicable vesting date. Read SEC document
September 02, 2021 Filed Sep 3, 2021 21:08 UTC	TANDEM DIABETES CARE INC TNDM · Entity 4682	SaleCommon Stock	300	$114.26	$34,278.00	Disclosure SEC source: 0001438133-21-000157 · wf-form4_163070329897998.xml · nonDerivative · entry 2 BLICKENSTAFF KIM D · CIK 0001238913 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 202,390 F3 · price: The price reported reflects the weighted average price per share of multiple transactions with prices per share ranging between $114.25 to $114.26. The Reporting Person undertakes to provide the Securitiesand Exchange Commission (the "SEC"), the issuer, and any security holder full information regarding the number of shares and the prices at which the shares were sold. F2 · ownership.nature: The securities are held by the Kim Blickenstaff Revocable Trust dated April 15, 2010. Read SEC document
September 02, 2021 Filed Sep 3, 2021 21:08 UTC	TANDEM DIABETES CARE INC TNDM · Entity 4682	SaleCommon Stock	28,400	$113.35	$3,219,140.00	Disclosure SEC source: 0001438133-21-000157 · wf-form4_163070329897998.xml · nonDerivative · entry 1 BLICKENSTAFF KIM D · CIK 0001238913 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 202,690 F1 · price: The price reported reflects the weighted average price per share of multiple transactions with prices per share ranging between $113.25 to $113.78. The Reporting Person undertakes to provide the Securitiesand Exchange Commission (the "SEC"), the issuer, and any security holder full information regarding the number of shares and the prices at which the shares were sold. F2 · ownership.nature: The securities are held by the Kim Blickenstaff Revocable Trust dated April 15, 2010. Read SEC document
August 27, 2021 Filed Aug 31, 2021 20:46 UTC	TANDEM DIABETES CARE INC TNDM · Entity 4682	Exercise / conversionSeries A Warrants · Derivative	28,700	$3.50 Strike: $3.50	$100,450.00	Disclosure SEC source: 0001438133-21-000155 · wf-form4_163044280063824.xml · derivative · entry 3 BLICKENSTAFF KIM D · CIK 0001238913 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 28,700 shares Expires 2022-10-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
August 27, 2021 Filed Aug 31, 2021 20:46 UTC	TANDEM DIABETES CARE INC TNDM · Entity 4682	Exercise / conversionCommon Stock	28,700	$3.50	$100,450.00	Disclosure SEC source: 0001438133-21-000155 · wf-form4_163044280063824.xml · nonDerivative · entry 1 BLICKENSTAFF KIM D · CIK 0001238913 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 231,090 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction reflects the cash exercise of warrants to purchase common stock, at an exercise price of $3.50. F2 · ownership.nature: The securities are held by the Kim Blickenstaff Revocable Trust dated April 15, 2010. Read SEC document
August 17, 2021 Filed Aug 18, 2021 20:22 UTC	TANDEM DIABETES CARE INC TNDM · Entity 4682	SaleCommon Stock	19,250	$109.12	$2,100,654.33	Disclosure SEC source: 0001438133-21-000135 · wf-form4_162931813578651.xml · nonDerivative · entry 3 BLICKENSTAFF KIM D · CIK 0001238913 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 202,390 F4 · price: The price reported reflects the weighted average price per share of multiple transactions with prices per share ranging between $109.10 to $109.13. The Reporting Person undertakes to provide the Securities and Exchange Commission (the "SEC"), the issuer, and any security holder full information regarding the number of shares and the prices at which the shares were sold. F2 · ownership.nature: The securities are held by the Kim Blickenstaff Revocable Trust dated April 15, 2010. Read SEC document
August 17, 2021 Filed Aug 18, 2021 20:22 UTC	TANDEM DIABETES CARE INC TNDM · Entity 4682	SaleCommon Stock	6,510	$108.09	$703,643.77	Disclosure SEC source: 0001438133-21-000135 · wf-form4_162931813578651.xml · nonDerivative · entry 2 BLICKENSTAFF KIM D · CIK 0001238913 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 221,640 F3 · price: The price reported reflects the weighted average price per share of multiple transactions with prices per share ranging between $108.00 to $108.88. The Reporting Person undertakes to provide the Securities and Exchange Commission (the "SEC"), the issuer, and any security holder full information regarding the number of shares and the prices at which the shares were sold. F2 · ownership.nature: The securities are held by the Kim Blickenstaff Revocable Trust dated April 15, 2010. Read SEC document
August 16, 2021 Filed Aug 18, 2021 20:22 UTC	TANDEM DIABETES CARE INC TNDM · Entity 4682	SaleCommon Stock	24,240	$109.07	$2,643,851.95	Disclosure SEC source: 0001438133-21-000135 · wf-form4_162931813578651.xml · nonDerivative · entry 1 BLICKENSTAFF KIM D · CIK 0001238913 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 228,150 F1 · price: The price reported reflects the weighted average price per share of multiple transactions with prices per share ranging between $109.00 to $109.46. The Reporting Person undertakes to provide the Securities and Exchange Commission (the "SEC"), the issuer, and any security holder full information regarding the number of shares and the prices at which the shares were sold. F2 · ownership.nature: The securities are held by the Kim Blickenstaff Revocable Trust dated April 15, 2010. Read SEC document
August 13, 2021 Filed Aug 16, 2021 20:45 UTC	TANDEM DIABETES CARE INC TNDM · Entity 4682	SaleCommon Stock	50,000	$107.20	$5,359,825.00	Disclosure SEC source: 0001438133-21-000133 · wf-form4_162914668846486.xml · nonDerivative · entry 2 BLICKENSTAFF KIM D · CIK 0001238913 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 252,390 F1 · kind: Shares sold are from long shares held by the Kim Blickenstaff Revocable Trust, dated April 15, 2010. F4 · price: The price reported reflects the weighted average price per share of multiple transactions with prices per share ranging between $106.74 to $107.70. The Reporting Person undertakes to provide the Securities and Exchange Commission (the "SEC"), the issuer, and any security holder full information regarding the number of shares and the prices at which the shares were sold. F3 · ownership.nature: The securities are held by the Kim Blickenstaff Revocable Trust dated April 15, 2010. Read SEC document
August 12, 2021 Filed Aug 16, 2021 20:45 UTC	TANDEM DIABETES CARE INC TNDM · Entity 4682	SaleCommon Stock	13,990	$105.50	$1,475,933.81	Disclosure SEC source: 0001438133-21-000133 · wf-form4_162914668846486.xml · nonDerivative · entry 1 BLICKENSTAFF KIM D · CIK 0001238913 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 302,390 F1 · kind: Shares sold are from long shares held by the Kim Blickenstaff Revocable Trust, dated April 15, 2010. F2 · price: The price reported reflects the weighted average price per share of multiple transactions with prices per share ranging between $105.41 to $105.54. The Reporting Person undertakes to provide the Securities and Exchange Commission (the "SEC"), the issuer, and any security holder full information regarding the number of shares and the prices at which the shares were sold. F3 · ownership.nature: The securities are held by the Kim Blickenstaff Revocable Trust dated April 15, 2010. Read SEC document
August 10, 2021 Filed Aug 12, 2021 21:07 UTC	TANDEM DIABETES CARE INC TNDM · Entity 4682	SaleCommon Stock	3,210	$107.21	$344,134.15	Disclosure SEC source: 0001438133-21-000129 · wf-form4_162880244096933.xml · nonDerivative · entry 1 BLICKENSTAFF KIM D · CIK 0001238913 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 316,380 F1 · shares: Shares sold are from long shares held by the Kim Blickenstaff Revocable Trust, dated April 15, 2010. F2 · price: The price reported reflects the weighted average price per share of multiple transactions with prices per share ranging between $107.00 to $107.76. The Reporting Person undertakes to provide the Securities and Exchange Commission (the "SEC"), the issuer, and any security holder full information regarding the number of shares and the prices at which the shares were sold. F3 · ownership.nature: The securities are held by the Kim Blickenstaff Revocable Trust dated April 15, 2010. Read SEC document
August 09, 2021 Filed Aug 10, 2021 20:27 UTC	TANDEM DIABETES CARE INC TNDM · Entity 4682	SaleCommon Stock	19,239	$107.64	$2,070,910.97	Disclosure SEC source: 0001438133-21-000125 · wf-form4_162862724851282.xml · nonDerivative · entry 3 BLICKENSTAFF KIM D · CIK 0001238913 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 319,590 F1 · shares: Shares sold are from long shares held by the Kim Blickenstaff Revocable Trust, dated April 15, 2010. F5 · price: The price reported reflects the weighted average price per share of multiple transactions with prices per share ranging between $108.00 to $108.63. The Reporting Person undertakes to provide the Securities and Exchange Commission (the "SEC"), the issuer, and any security holder full information regarding the number of shares and the prices at which the shares were sold. F3 · ownership.nature: The securities are held by the Kim Blickenstaff Revocable Trust dated April 15, 2010. Read SEC document
August 09, 2021 Filed Aug 10, 2021 20:27 UTC	TANDEM DIABETES CARE INC TNDM · Entity 4682	SaleCommon Stock	60,761	$107.64	$6,540,393.03	Disclosure SEC source: 0001438133-21-000125 · wf-form4_162862724851282.xml · nonDerivative · entry 2 BLICKENSTAFF KIM D · CIK 0001238913 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 338,829 F1 · shares: Shares sold are from long shares held by the Kim Blickenstaff Revocable Trust, dated April 15, 2010. F4 · price: The price reported reflects the weighted average price per share of multiple transactions with prices per share ranging between $107.00 to $107.98. The Reporting Person undertakes to provide the Securities and Exchange Commission (the "SEC"), the issuer, and any security holder full information regarding the number of shares and the prices at which the shares were sold. F3 · ownership.nature: The securities are held by the Kim Blickenstaff Revocable Trust dated April 15, 2010. Read SEC document
August 06, 2021 Filed Aug 10, 2021 20:27 UTC	TANDEM DIABETES CARE INC TNDM · Entity 4682	SaleCommon Stock	2,800	$109.39	$306,302.92	Disclosure SEC source: 0001438133-21-000125 · wf-form4_162862724851282.xml · nonDerivative · entry 1 BLICKENSTAFF KIM D · CIK 0001238913 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 399,590 F1 · shares: Shares sold are from long shares held by the Kim Blickenstaff Revocable Trust, dated April 15, 2010. F2 · price: The price reported reflects the weighted average price per share of multiple transactions with prices per share ranging between $109.01 to $109.71. The Reporting Person undertakes to provide the Securities and Exchange Commission (the "SEC"), the issuer, and any security holder full information regarding the number of shares and the prices at which the shares were sold. F3 · ownership.nature: The securities are held by the Kim Blickenstaff Revocable Trust dated April 15, 2010. Read SEC document
June 11, 2021 Filed Jun 15, 2021 20:41 UTC	TANDEM DIABETES CARE INC TNDM · Entity 4682	GiftCommon Stock	1,000	$91.51	$91,510.00	Disclosure SEC source: 0001438133-21-000102 · wf-form4_162378963169669.xml · nonDerivative · entry 3 BLICKENSTAFF KIM D · CIK 0001238913 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 402,390 F5 · kind: The shares were given as a bona fide gift to Martin F. Perdoux. F2 · price: The price per share reflects the average of the high and low trading prices of the Company's stock on the transaction date. F3 · ownership.nature: The securities are held by the Kim Blickenstaff Revocable Trust dated April 15, 2010. Read SEC document
June 11, 2021 Filed Jun 15, 2021 20:41 UTC	TANDEM DIABETES CARE INC TNDM · Entity 4682	GiftCommon Stock	1,000	$91.51	$91,510.00	Disclosure SEC source: 0001438133-21-000102 · wf-form4_162378963169669.xml · nonDerivative · entry 2 BLICKENSTAFF KIM D · CIK 0001238913 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 403,390 F4 · kind: The shares were given as a bona fide gift to Eileen M. Favorite. F2 · price: The price per share reflects the average of the high and low trading prices of the Company's stock on the transaction date. F3 · ownership.nature: The securities are held by the Kim Blickenstaff Revocable Trust dated April 15, 2010. Read SEC document
June 11, 2021 Filed Jun 15, 2021 20:41 UTC	TANDEM DIABETES CARE INC TNDM · Entity 4682	GiftCommon Stock	10,000	$91.51	$915,100.00	Disclosure SEC source: 0001438133-21-000102 · wf-form4_162378963169669.xml · nonDerivative · entry 1 BLICKENSTAFF KIM D · CIK 0001238913 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 404,390 F1 · kind: The shares were given as a bona fide gift to KDB Peoria Women's Club Fund. F2 · price: The price per share reflects the average of the high and low trading prices of the Company's stock on the transaction date. F3 · ownership.nature: The securities are held by the Kim Blickenstaff Revocable Trust dated April 15, 2010. Read SEC document
June 08, 2021 Filed Jun 10, 2021 20:57 UTC	TANDEM DIABETES CARE INC TNDM · Entity 4682	SaleCommon Stock	2,800	$89.25	$249,901.12	Disclosure SEC source: 0001438133-21-000096 · wf-form4_162335863493704.xml · nonDerivative · entry 3 BLICKENSTAFF KIM D · CIK 0001238913 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 414,390 F1 · shares: Shares sold are from long shares held by the Kim Blickenstaff Revocable Trust, dated April 15, 2010. F5 · price: The price reported reflects the weighted average price per share of multiple transactions with prices per share ranging between $88.90 to $89.57. The Reporting Person undertakes to provide the Securities and Exchange Commission (the "SEC"), the issuer, and any security holder full information regarding the number of shares and the prices at which the shares were sold. F3 · ownership.nature: The securities are held by the Kim Blickenstaff Revocable Trust dated April 15, 2010. Read SEC document
June 08, 2021 Filed Jun 10, 2021 20:57 UTC	TANDEM DIABETES CARE INC TNDM · Entity 4682	SaleCommon Stock	18,077	$88.66	$1,602,658.01	Disclosure SEC source: 0001438133-21-000096 · wf-form4_162335863493704.xml · nonDerivative · entry 2 BLICKENSTAFF KIM D · CIK 0001238913 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 417,190 F1 · shares: Shares sold are from long shares held by the Kim Blickenstaff Revocable Trust, dated April 15, 2010. F4 · price: The price reported reflects the weighted average price per share of multiple transactions with prices per share ranging between $88.00 to $88.88. The Reporting Person undertakes to provide the Securities and Exchange Commission (the "SEC"), the issuer, and any security holder full information regarding the number of shares and the prices at which the shares were sold. F3 · ownership.nature: The securities are held by the Kim Blickenstaff Revocable Trust dated April 15, 2010. Read SEC document
June 08, 2021 Filed Jun 10, 2021 20:57 UTC	TANDEM DIABETES CARE INC TNDM · Entity 4682	SaleCommon Stock	17,123	$87.41	$1,496,721.43	Disclosure SEC source: 0001438133-21-000096 · wf-form4_162335863493704.xml · nonDerivative · entry 1 BLICKENSTAFF KIM D · CIK 0001238913 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 435,267 F1 · shares: Shares sold are from long shares held by the Kim Blickenstaff Revocable Trust, dated April 15, 2010. F2 · price: The price reported reflects the weighted average price per share of multiple transactions with prices per share ranging between $87.00 to $87.87. The Reporting Person undertakes to provide the Securities and Exchange Commission (the "SEC"), the issuer, and any security holder full information regarding the number of shares and the prices at which the shares were sold. F3 · ownership.nature: The securities are held by the Kim Blickenstaff Revocable Trust dated April 15, 2010. Read SEC document
May 27, 2021 Filed Jun 1, 2021 23:19 UTC	TANDEM DIABETES CARE INC TNDM · Entity 4682	Exercise / conversionRestricted Stock Unit · Derivative	1,892	$0.00	$0.00	Disclosure SEC source: 0001438133-21-000081 · wf-form4_162258954202618.xml · derivative · entry 3 BLICKENSTAFF KIM D · CIK 0001238913 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,892 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Granted pursuant to the Tandem Diabetes Care, Inc. 2013 Stock Incentive Plan (the 2013 Plan). F3 · derivative.exercise_price: Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of the Company. F4 · kind: This RSU award was granted on May 27, 2020. 100% of the RSU vested on May 27, 2021. F5 · derivative.exercise_date: RSU vest as to one-hundred percent (100%) of the total number of shares subject to the RSU on 5/27/2021. F5 · derivative.expiration_date: RSU vest as to one-hundred percent (100%) of the total number of shares subject to the RSU on 5/27/2021. Read SEC document
May 27, 2021 Filed Jun 1, 2021 23:19 UTC	TANDEM DIABETES CARE INC TNDM · Entity 4682	Exercise / conversionCommon Stock	1,892	$0.00	$0.00	Disclosure SEC source: 0001438133-21-000081 · wf-form4_162258954202618.xml · nonDerivative · entry 1 BLICKENSTAFF KIM D · CIK 0001238913 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,892 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
May 18, 2021 Filed May 21, 2021 01:17 UTC	TANDEM DIABETES CARE INC TNDM · Entity 4682	GrantRestricted Stock Unit · Derivative	2,205	$0.00	$0.00	Disclosure SEC source: 0001438133-21-000043 · wf-form4_162155981262640.xml · derivative · entry 1 BLICKENSTAFF KIM D · CIK 0001238913 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,205 Underlying: Common Stock · 2,205 shares Expires not disclosed F1 · security: Awarded on May 18, 2021 pursuant to the Tandem Diabetes Care, Inc. 2013 Stock Incentive Plan, as amended, and the agreements related thereto (the "2013 Plan"). F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2013 Plan. F3 · derivative.exercise_date: RSU will vest on the one-year anniversary of the grant date, subject to the terms of the 2013 Plan. F3 · derivative.expiration_date: RSU will vest on the one-year anniversary of the grant date, subject to the terms of the 2013 Plan. Read SEC document
March 16, 2021 Filed Mar 17, 2021 21:52 UTC	TANDEM DIABETES CARE INC TNDM · Entity 4682	SaleCommon Stock	1,100	$88.85	$97,738.96	Disclosure SEC source: 0001438133-21-000021 · wf-form4_161601788924421.xml · nonDerivative · entry 6 BLICKENSTAFF KIM D · CIK 0001238913 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 452,390 F1 · shares: Shares sold are from long shares held by the Kim Blickenstaff Revocable Trust, dated April 15, 2010. F8 · price: The price reported reflects the weighted average price per share of multiple transactions with prices per share ranging between $88.73 to $88.99. The Reporting Person undertakes to provide the Securities and Exchange Commission (the "SEC"), the issuer, and any security holder full information regarding the number of shares and the prices at which the shares were sold. F3 · ownership.nature: The securities are held by the Kim Blickenstaff Revocable Trust dated April 15, 2010. Read SEC document
March 16, 2021 Filed Mar 17, 2021 21:52 UTC	TANDEM DIABETES CARE INC TNDM · Entity 4682	SaleCommon Stock	23,828	$88.18	$2,101,055.35	Disclosure SEC source: 0001438133-21-000021 · wf-form4_161601788924421.xml · nonDerivative · entry 5 BLICKENSTAFF KIM D · CIK 0001238913 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 453,490 F1 · shares: Shares sold are from long shares held by the Kim Blickenstaff Revocable Trust, dated April 15, 2010. F7 · price: The price reported reflects the weighted average price per share of multiple transactions with prices per share ranging between $87.71 to $88.70. The Reporting Person undertakes to provide the Securities and Exchange Commission (the "SEC"), the issuer, and any security holder full information regarding the number of shares and the prices at which the shares were sold. F3 · ownership.nature: The securities are held by the Kim Blickenstaff Revocable Trust dated April 15, 2010. Read SEC document
March 16, 2021 Filed Mar 17, 2021 21:52 UTC	TANDEM DIABETES CARE INC TNDM · Entity 4682	SaleCommon Stock	20,594	$87.19	$1,795,564.09	Disclosure SEC source: 0001438133-21-000021 · wf-form4_161601788924421.xml · nonDerivative · entry 4 BLICKENSTAFF KIM D · CIK 0001238913 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 477,318 F1 · shares: Shares sold are from long shares held by the Kim Blickenstaff Revocable Trust, dated April 15, 2010. F6 · price: The price reported reflects the weighted average price per share of multiple transactions with prices per share ranging between $86.71 to $87.70. The Reporting Person undertakes to provide the Securities and Exchange Commission (the "SEC"), the issuer, and any security holder full information regarding the number of shares and the prices at which the shares were sold. F3 · ownership.nature: The securities are held by the Kim Blickenstaff Revocable Trust dated April 15, 2010. Read SEC document
March 16, 2021 Filed Mar 17, 2021 21:52 UTC	TANDEM DIABETES CARE INC TNDM · Entity 4682	SaleCommon Stock	5,500	$85.96	$472,769.00	Disclosure SEC source: 0001438133-21-000021 · wf-form4_161601788924421.xml · nonDerivative · entry 3 BLICKENSTAFF KIM D · CIK 0001238913 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 497,912 F1 · shares: Shares sold are from long shares held by the Kim Blickenstaff Revocable Trust, dated April 15, 2010. F5 · price: The price reported reflects the weighted average price per share of multiple transactions with prices per share ranging between $85.58 to $86.56. The Reporting Person undertakes to provide the Securities and Exchange Commission (the "SEC"), the issuer, and any security holder full information regarding the number of shares and the prices at which the shares were sold. F3 · ownership.nature: The securities are held by the Kim Blickenstaff Revocable Trust dated April 15, 2010. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.